Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Federico Rojo; Clive R. Taylor; Carlos H. Barrios; Laura Torrecillas; Manuel Ruíz-Borrego; Sandra Pérez‐Buira; José Bines; Ángel Guerrero‐Zotano; José Á. García-Sáenz; Roberto Torres; Juan de la Haba-Rodríguez; Francisco Ayala; Henry Gómez; Antonio Llombart‐Cussac; María Rodríguez de la Borbolla; José Manuel Baena-Cañada; Agustí Barnadas; Lourdes Calvo; Jesús Herránz; Raúl Rincón; Rosalía Caballero; Begoña Bermejo; Partha S. Ray; Miguel Martín

doi:10.1158/1078-0432.30029038

Key Points

FOXC1 expression predicts capecitabine efficacy, enhancing recurrence-free survival for patients.
The primary endpoint showed significant results for recurrence-free survival between treatment arms: capecitabine vs observation.
A translational study assessed outcomes in triple-negative breast cancer patients treated within the GEICAM_CIBOMA trial.
This highlights FOXC1 as a potential biomarker in tailoring treatments for triple-negative breast cancer.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This analysis reveals the impact of FOXC1 expression on recurrence-free survival in patients, implying a potential biomarker for treatment response.

Abstract

Forest plot for the GEICAM_CIBOMA translational study cohort primary endpoint of recurrence-free survival (RFS) on the capecitabine arm versus observation arm for basal-like/non-basal categories variables

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rojo et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5c2 https://doi.org/10.1158/1078-0432.30029038

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading